Innovative DNA Synthesis DNA Script's enzymatic DNA synthesis technology, exemplified by the SYNTAX™️ platform, offers a cutting-edge alternative to traditional methods, creating opportunities to sell advanced reagents and consumables tailored for this revolutionary approach.

Strategic Partnerships Recent collaborations, such as the partnership with EVA Pharma and Quantoom Biosciences in Egypt, highlight opportunities to expand into emerging markets and support joint ventures that require specialized enzymatic synthesis solutions and mRNA production capabilities.

Recent Market Launches The commercial release of the SYNTAX DNA printing platform and related programs indicates readiness to onboard early adopters and research institutions seeking integrated, automated DNA synthesis solutions, opening avenues for sales and service support.

Growth and Investment With Series C funding exceeding $38 million and revenues between $10M and $25M, DNA Script is positioned for rapid expansion, presenting sales opportunities in infrastructure, reagent supplies, and technical support as the company scales operations.

Technological Leadership As a leader in enzymatic DNA synthesis technology, DNA Script can be a key partner for biotech firms, research institutions, and pharmaceutical companies looking to innovate in genomics, personalized medicine, and vaccine development, fostering long-term sales collaborations.